Form 4: ADC Therapeutics Director Sells Shares to Cover Tax Obligations

Viviane Monges, a Director at ADC Therapeutics SA, disposed of 2,584 common shares valued at $3.58 per share to satisfy tax withholding obligations related to vested restricted share units.

Summary

• Viviane Monges, a Director of ADC Therapeutics SA (ADCT), reported a transaction involving the company's common shares.
• On June 13, 2025, Ms. Monges disposed of 2,584 common shares.
• The shares were disposed of at a price of $3.58 per share.
• This transaction was identified as a 'F' transaction code, indicating shares withheld by the Issuer to cover tax withholding obligations associated with the vesting of previously granted restricted share units.
• Following this transaction, Viviane Monges directly beneficially owns 144,043 common shares of ADC Therapeutics SA.

Sentiment

Score: 5

Explanation: The transaction is neutral in sentiment as it represents a routine tax-related disposition of shares upon vesting of restricted stock units, rather than a discretionary sale or purchase.

Positives

• The transaction is a routine event for directors receiving equity compensation, indicating the vesting of previously granted restricted share units.

Negatives

• The disposition of shares, even for tax purposes, reduces the director's direct ownership in the company, which could be perceived as a slight decrease in direct alignment with shareholder interests, though it's a common practice.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and tax obligations, which is common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where ADC Therapeutics operates.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of restricted share units is a standard compensation and tax management practice for executives and directors across publicly traded companies globally. There are no specific comparable companies or projects mentioned in this filing to assess against industry-specific results.

Stakeholder Impact

• Shareholders: The transaction is a minor, non-discretionary reduction in a director's direct shareholding, unlikely to have a significant impact on shareholder sentiment or company valuation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

ADC Therapeutics, ADCT, Viviane Monges, SEC Form 4, Insider Transaction, Share Disposition, Tax Withholding, Restricted Share Units, Director Shareholding